Cardiac Rhythm Management (sometimes called by its initials, CRM) is the area that Admittance works in. This area can be divided into two major classes of devices:
1) a pacemaker, which paces your heart when it’s going too slow, and
2) a defibrillator, which shocks your heart to reset it when it’s going too fast.
When these devices have three leads, including the one in yellow in the diagram, they are called Cardiac Resynchronization Therapy devices, or CRTs. CRT devices have been proven to be effective in improving heart failure patients by synchronizing the two main chambers in the heart.
Admittance is an instrumentation design company that can take advantage of the technology already implanted in patients, with the goal of improving their care.
At its most basic level, the heart is a pump. When the heart is adequately pumping blood to the body, we feel fine. The amount of blood the heart pumps with each stroke is called the Stroke Volume (SV). When doctors or medical professionals have to decide whether to shock (or defibrillate) a patient who is in the hospital, they consider stroke volume (or a proxy for stroke volume such as blood pressure) along with ECG readings. However, when a patient has an implantable defibrillator and is not in the hospital, current implantable defibrillators only have access to ECG data and not SV in order to determine when to shock. Knowing the stroke volume could assist the implantable defibrillator in evaluating the condition of the heart to make more appropriate shock decisions. .
CardioVol™ uses a proprietary algorithm and current waveforms to determine relative volume in the heart using leads already implanted in patients with CRT devices. This is what CardioVol™ measures compared to a standard of volume (Sonomicrometry crystals, or Sono SV):
And when the SV changes, CardioVolTM can pick it up too. The SV was changed in this study by overdrive pacing to reduce SV, and then dopamine infusion to increase SV: